PMC:7417114 / 32011-32485 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T365","span":{"begin":134,"end":140},"obj":"Disease"},{"id":"T366","span":{"begin":141,"end":150},"obj":"Disease"},{"id":"T367","span":{"begin":284,"end":292},"obj":"Disease"},{"id":"T368","span":{"begin":460,"end":463},"obj":"Disease"}],"attributes":[{"id":"A365","pred":"mondo_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/MONDO_0005502"},{"id":"A366","pred":"mondo_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A367","pred":"mondo_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A368","pred":"mondo_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/MONDO_0018874"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T393","span":{"begin":16,"end":17},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T394","span":{"begin":267,"end":275},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T395","span":{"begin":377,"end":380},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T396","span":{"begin":426,"end":430},"obj":"http://purl.obolibrary.org/obo/PR_000002001"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T283","span":{"begin":25,"end":34},"obj":"Chemical"},{"id":"T284","span":{"begin":79,"end":88},"obj":"Chemical"},{"id":"T285","span":{"begin":93,"end":102},"obj":"Chemical"},{"id":"T286","span":{"begin":244,"end":249},"obj":"Chemical"}],"attributes":[{"id":"A283","pred":"chebi_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A284","pred":"chebi_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/CHEBI_38940"},{"id":"A285","pred":"chebi_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/CHEBI_114785"},{"id":"A286","pred":"chebi_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1111","span":{"begin":38,"end":41},"obj":"Gene"},{"id":"1112","span":{"begin":426,"end":430},"obj":"Gene"},{"id":"1113","span":{"begin":284,"end":294},"obj":"Species"},{"id":"1114","span":{"begin":405,"end":413},"obj":"Species"},{"id":"1115","span":{"begin":0,"end":12},"obj":"Chemical"},{"id":"1116","span":{"begin":79,"end":88},"obj":"Chemical"},{"id":"1117","span":{"begin":93,"end":102},"obj":"Chemical"},{"id":"1118","span":{"begin":157,"end":169},"obj":"Chemical"},{"id":"1119","span":{"begin":364,"end":376},"obj":"Chemical"},{"id":"1120","span":{"begin":141,"end":150},"obj":"Disease"},{"id":"1121","span":{"begin":460,"end":463},"obj":"Disease"}],"attributes":[{"id":"A1111","pred":"tao:has_database_id","subj":"1111","obj":"Gene:558"},{"id":"A1112","pred":"tao:has_database_id","subj":"1112","obj":"Gene:2322"},{"id":"A1113","pred":"tao:has_database_id","subj":"1113","obj":"Tax:2697049"},{"id":"A1114","pred":"tao:has_database_id","subj":"1114","obj":"Tax:9606"},{"id":"A1115","pred":"tao:has_database_id","subj":"1115","obj":"MESH:C000609080"},{"id":"A1116","pred":"tao:has_database_id","subj":"1116","obj":"MESH:D000077210"},{"id":"A1117","pred":"tao:has_database_id","subj":"1117","obj":"MESH:D000069347"},{"id":"A1118","pred":"tao:has_database_id","subj":"1118","obj":"MESH:C000609080"},{"id":"A1119","pred":"tao:has_database_id","subj":"1119","obj":"MESH:C000609080"},{"id":"A1120","pred":"tao:has_database_id","subj":"1120","obj":"MESH:D007239"},{"id":"A1121","pred":"tao:has_database_id","subj":"1121","obj":"MESH:D015470"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T86","span":{"begin":460,"end":463},"obj":"Phenotype"}],"attributes":[{"id":"A86","pred":"hp_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/HP_0004808"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T251","span":{"begin":0,"end":156},"obj":"Sentence"},{"id":"T252","span":{"begin":157,"end":325},"obj":"Sentence"},{"id":"T253","span":{"begin":326,"end":363},"obj":"Sentence"},{"id":"T254","span":{"begin":364,"end":474},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"2_test","denotations":[{"id":"32778962-27908881-84130657","span":{"begin":43,"end":45},"obj":"27908881"},{"id":"32778962-28240606-84130658","span":{"begin":152,"end":154},"obj":"28240606"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T2195","span":{"begin":145,"end":190},"obj":"GO:0065007"}],"text":"Gilteritinib is a potent inhibitor of AXL (49), which is one of the targets of sunitinib and erlotinib identified to be important for dengue infection (46). Gilteritinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Gilteritinib has been approved for adult patients with mutant FLT3-positive refractory/relapsed AML (Table 2)."}